Navigation Links
China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.

LAS VEGAS and BEIJING, Sept. 10 /Xinhua-PRNewswire-FirstCall/ -- China Holdings, Inc. (OTC Bulletin Board: CHHL), a development stage company with the goal of becoming a leading diversified global asset holding company and engaged in multiple China-focused business activities including pharmaceutical, real estate, utilities, energy, renewable-energy and finance, today announced that the Company has appointed Mr. Shon as Chairman of the Advisory Board to its wholly-owned subsidiary, China Power, Inc., to assist the Company's strategic development, corporate financing worldwide. Mr. Shon will be given responsibility for corporate finance, investment transactions, and global corporate strategy in both China Holdings, Inc. and China Power, Inc.

Mr. Shon has been the Chairman of Advisory Board of China Holdings, Inc. since early 2007. He is the President of The Shon Group of Companies, a group of privately held real estate investment and development companies which hold the AAA+ Cathedral Office Building in downtown Vancouver, Canada. In addition, Mr. Shon is also the President of China Education Resources Inc., and a director of the Spectra Group of Great Restaurants Inc. Mr. Shon holds a B.A. from Stanford University and a M.B.A. from the Wharton School, University of Pennsylvania.

''Mr. Ronald Shon's extensive successful experiences in investment and transaction advisory services expertise in North America will greatly benefit both CHINA HOLDINGS, INC. and CHINA POWER, INC. as we continue to expand our business. We are very grateful to have Mr. Ronaldson Shon's further valuable contributions to our Companies as the Chairman of Advisory Board,'' said Julianna Lu, the Founder and CEO of both China Holdings, Inc. and China Power, Inc.

About China Holdings, Inc.

China Holdings, Inc. (NASD OTC Bulletin Board: CHHL) is a development stage company with the goal of becoming a diversified global asset holding company. The Company and its subsidiaries engage in multiple China-focused business activities including pharmaceutical, real estate, utilities, energy and finance. Its objective is to achieve long-term capital appreciation through investment in companies and other entities with significant assets, investments, production activities, trading or other business interests in China, and/or worldwide, and/or which derive a significant part of their revenue from China, and/or worldwide.

The Company has two wholly-owned subsidiaries: (i) China Power, Inc., and (ii) China Health Holdings, Inc. For more information, please see the Company's website at: .

About China Power, Inc.

China Power Inc., a wholly owned subsidiary of China Holdings, Inc. (OTCBB: CHHL), is a development stage company with the goal of becoming a global leading energy holding corporation, that focuses on the Merger & Acquisition, investment, Research & Development, construction and operation of energy, and renewable energy, and environment protection projects in China and worldwide. It expects to capture China's growing energy, renewable energy, and environment protection projects domestically and worldwide.

For worldwide investor and media inquiries, please contact:

China Holdings, Inc. (OTCBB: CHHL) and China Power, Inc.

Las Vegas and Beijing

Julianna Lu, Chief Executive Officer, or

James H. Simpson, Senior Vice President/Investor Relations

Tel: +86-10-6586-4770

Fax: +86-10-6586-4790

Mobile: +86-1370-133-1287



Investor Relations International (Los Angeles)

Haris Tajyar

Managing Director

Tel: +1-818-382-9700

Safe Harbor Statement: To the extent that statements in the press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward looking, all forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements, which may accompany the forward-looking statements, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Other important factors that could cause actual results to differ materially include the following: business conditions and the amount of growth in the Company's industry and general economy; competitive factors; ability to attract and retain personnel; the price of the Company's stock; and the risk factors set forth from time to time in the Company's SEC reports, including but not limited to its annual report on Form 10-KSB; its quarterly reports on Forms 10-QSB; and any reports on Form 8-K. In addition, the company disclaims any obligation to update or correct any forward-looking statements in all of the Company's press releases to reflect events or circumstances after the date hereof.

SOURCE China Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. China tells officials not to hide SARS damage
2. China reports declining number of SARS Cases
3. China says patient may have SARS
4. 15 Anti-SARS Drugs Identified By China-Europe Team of Researchers
5. Adverse Effects Associated with Unauthorised Hepatitis A Vaccine in China
6. Pig Bacterium (Streptococcus suis) Kills 24 In China
7. Watch Out! Pollution hazard from E-waste recycling in India & China
8. French Fries In Cancer Controversy In China
9. China To Distribute Free Condoms To Combat AIDS/HIV
10. HIV Cases Steadily Increasing In China With The Toll Over 1.26 Lakh
11. India And China Discuss Import Of Encephalitis Vaccine
Post Your Comments:
(Date:12/1/2015)... ... ... ClinicoEconomics and Outcomes Research has published the ... ”. , As corresponding author Dr Ankita Modi says “Pre-existing gastrointestinal events may ... a large US managed care database, women aged 55 years or older with ...
(Date:12/1/2015)... ... December 01, 2015 , ... Physicians’ Education Resource®, ... (CME), today announced that the first annual School of Gastrointestinal Oncology™ (SOGO™) will ... detection and treatment of gastrointestinal cancers are undergoing transformational change, providing oncologists with ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Growth in ... part due to decreases in utilization of hospital and nonhospital care, according to a ... CompScope™ Medical Benchmarks for Louisiana, 16th Edition , found medical payments per claim with ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... medical images have been lifted as IMAGE Information Systems launches MED-TAB™ -- the ... North America Annual Meeting from November 29 to December 4, 2015. , ...
(Date:12/1/2015)... ... December 01, 2015 , ... Visage ... (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced ... Radiological Society of North America (RSNA) 2015 annual meeting through December 3 in ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015 Breg, Inc ., a premier ... that it has been awarded three contracts by Novation, ... Novation will have access to improved pricing for Breg,s ... soft goods dedicated to advancing orthopedic care.  ... U.S. population, rising prevalence of chronic conditions and the ...
(Date:12/1/2015)... , December 1, 2015 Russia ... III clinical trials. 70% of new drugs registered in Europe ... in Russia . --> Russia has always ... 70% of new drugs registered in Europe in ... --> Russia has always been a ...
(Date:12/1/2015)... 1, 2015 CytRx Corporation (NASDAQ: CYTR ... oncology, today announced that it has reached its enrollment ... Phase 3 clinical trial of aldoxorubicin in patients with ... to be completed in Q1 2016. The Phase 3 trial ... Special Protocol Assessment from the FDA at 79 sites ...
Breaking Medicine Technology: